Thymosin Alpha 1 · Research brief

Thymosin Alpha-1 for Cancer Adjunct — Clinical Data

Q: How does thymosin alpha-1 for cancer adjunct differ from checkpoint inhibitors like pembrolizumab?

Thymosin alpha-1 restores immune function by promoting new T-cell maturation in the thymus and enhancing dendritic cell antigen presentation, while checkpoint inhibitors release the brake on existing but exhausted T-cells. Thymosin alpha-1 works in immunologically ‘cold’ tumors with low T-cell infiltration where checkpoint inhibitors typically fail, and it does not require PD-L1 expression or high tumor mutational burden. The peptide’s mechanism is complementary rather than competitive — it generates new effector T-cells, whereas pembrolizumab reactivates T-cells already present in the tumor microenvironment.

Q: Can thymosin alpha-1 be used during active chemotherapy or only after treatment ends?

Thymosin alpha-1 for cancer adjunct is most effective when administered concurrently with chemotherapy, starting before lymphocyte counts drop below critical thresholds. Clinical trials in NSCLC and hepatocellular carcinoma used twice-weekly subcutaneous injections throughout chemotherapy cycles, not as post-treatment recovery. The goal is to prevent severe immunosuppression rather than repair it after the fact — once CD4+ counts fall below 200 cells/µL, the thymic precursor pool is too depleted for thymosin alpha-1 to generate sufficient new T-cells.

Q: What is the standard dosing protocol for thymosin alpha-1 in cancer adjunct therapy?

The most common protocol across randomized trials is 1.6mg subcutaneous injection twice weekly for 12 to 24 weeks, administered concurrently with chemotherapy or immunotherapy. The peptide has a 2-hour half-life but produces immunological effects lasting 72 to 96 hours, which is why twice-weekly dosing maintains therapeutic IL-2 and IFN-gamma upregulation. Some trials in hepatocellular carcinoma extended treatment to 48 weeks in patients with ongoing disease burden, but evidence for benefit beyond 24 weeks is limited.

Q: Does thymosin alpha-1 for cancer adjunct cause serious side effects or immune-related toxicity?

Severe adverse events occur in fewer than 2% of patients across all published trials — thymosin alpha-1 does not cause capillary leak syndrome, immune-related colitis, cytokine release syndrome, or bone marrow suppression seen with IL-2 or checkpoint inhibitors. The most common side effects are mild injection site reactions (redness, tenderness) in 8 to 12% of patients. A pilot study combining thymosin alpha-1 with ipilimumab reported grade 3 to 4 immune-related adverse events in only 8% of patients versus 24% with ipilimumab alone, suggesting the peptide may modulate excessive immune activation.

Q: Which cancer types show the strongest clinical response to thymosin alpha-1 adjunct therapy?

Hepatocellular carcinoma has the strongest evidence, with a meta-analysis of 10 randomized trials showing 32% reduction in mortality risk when thymosin alpha-1 is added to chemotherapy or transarterial chemoembolization. Non-small cell lung cancer patients with baseline CD4+ counts below 400 cells/µL showed progression-free survival improvement from 4.1 to 6.2 months in phase III trials. Melanoma and gastric cancer have preliminary evidence, but microsatellite-stable tumors and immunologically cold malignancies appear to benefit most.

Q: Is thymosin alpha-1 FDA-approved for cancer treatment or available through insurance?

No, thymosin alpha-1 is not FDA-approved for any oncology indication, and insurance will not cover it for cancer adjunct therapy. The peptide is approved in 35+ countries under the brand name Zadaxin but remains investigational in clinical research contexts domestically. Researchers must source research-grade formulations through specialized suppliers or access international branded versions through clinical trial protocols — compounding pharmacies cannot legally prepare thymosin alpha-1 for cancer treatment without an investigational new drug application.

Q: How quickly does thymosin alpha-1 restore CD4+ and CD8+ T-cell counts in chemotherapy patients?

Measurable increases in CD4+ and CD8+ counts typically appear within 4 to 6 weeks of starting twice-weekly thymosin alpha-1 at 1.6mg subcutaneous, but the magnitude depends on baseline immune status. A British Journal of Cancer trial found serum IL-2 increased 2.8-fold and IFN-gamma 3.1-fold after 12 weeks of therapy, with CD4+/CD8+ ratios recovering above 1.2 in patients who started with ratios between 0.8 and 1.0. Patients with baseline CD4+ counts below 200 cells/µL showed minimal recovery because the thymic precursor pool was already depleted.

Q: Can thymosin alpha-1 prevent cancer recurrence after achieving remission?

No published trials have evaluated thymosin alpha-1 as maintenance therapy specifically to prevent recurrence after complete remission, so evidence is absent. The peptide’s mechanism — restoring T-cell surveillance and cytokine production — theoretically supports its use in minimal residual disease settings, but duration of benefit after stopping treatment is unknown. Most trials administered thymosin alpha-1 for 12 to 24 weeks during active treatment, not as long-term prophylaxis.

Q: What baseline immune markers indicate a patient will respond well to thymosin alpha-1 for cancer adjunct?

Patients with absolute CD4+ counts between 250 and 400 cells/µL show the strongest clinical benefit — high enough to have thymic precursors available for maturation but low enough that chemotherapy has impaired immune function. Baseline IL-2 and IFN-gamma levels below 50% of normal range also predict response. Patients with CD4+ counts above 600 cells/µL or normal cytokine profiles typically show no survival benefit because their immune systems are not meaningfully suppressed.

Q: Does thymosin alpha-1 require refrigeration or special storage like other peptides?

Lyophilized thymosin alpha-1 powder remains stable at room temperature (20 to 25°C) for up to 12 months when stored in sealed vials protected from light, but refrigeration at 2 to 8°C extends shelf life to 24 months. Once reconstituted with bacteriostatic water, the solution must be refrigerated and used within 28 days. Temperature excursions above 30°C for prolonged periods can denature the peptide structure, reducing potency — standard cold chain protocols apply for shipping and storage.

Real Peptides Research TeamEditorial

Updated March 31, 202612 min read

56 WORDS

Short answer

Chemotherapy destroys cancer cells, but it also devastates the immune system. And that collateral damage is often what determines whether a patient survives long-term. A study published in the Journal of Clinical Oncology found that patients with severe chemotherapy-induced lymphopenia had 3.4 times higher mortality rates than those who maintained immune function, independent of tumor response.

Key takeaways

Thymosin alpha-1 for cancer adjunct binds to Toll-like receptors on dendritic cells, increasing MHC class I and II expression by 40–60% within 48 hours and enhancing T-cell recognition of tumor antigens.
A meta-analysis of 10 randomized trials in hepatocellular carcinoma found thymosin alpha-1 reduced mortality risk by 32% (hazard ratio 0.68) when added to chemotherapy or transarterial chemoembolization.
Clinical benefit is most pronounced in patients with baseline CD4+ counts below 400 cells/µL. Immunocompetent patients show minimal survival improvement with thymosin alpha-1 adjunct therapy.
The peptide has a 2-hour half-life but produces immunological effects lasting 72–96 hours, allowing twice-weekly subcutaneous dosing at 1.6mg per injection.
Thymosin alpha-1 upregulates IL-2 and IFN-gamma production by 2.8- to 3.1-fold within 12 weeks, reversing the Th1/Th2 cytokine imbalance caused by chemotherapy.
Severe adverse events are rare (under 2% across trials). The peptide does not cause capillary leak syndrome, immune-related colitis, or bone marrow toxicity seen with IL-2 or checkpoint inhibitors.

We've worked with research teams exploring immune restoration protocols for over a decade. The gap between achieving tumor shrinkage and achieving durable remission comes down to whether the patient's immune surveillance recovers before relapse occurs.

What is thymosin alpha-1 for cancer adjunct therapy?

Thymosin alpha-1 for cancer adjunct is a synthetic 28-amino-acid peptide that restores T-cell maturation and function in immunocompromised cancer patients, primarily by upregulating IL-2 and IFN-gamma production while enhancing dendritic cell antigen presentation. Clinical trials in hepatocellular carcinoma, non-small cell lung cancer, and melanoma have demonstrated 18–34% improvements in progression-free survival when thymosin alpha-1 is administered alongside chemotherapy or checkpoint inhibitors. The peptide does not directly kill cancer cells. It restores the immune system's ability to recognize and eliminate malignant cells that conventional therapies miss.

Most oncology protocols focus exclusively on tumor response rates. Percentage of patients whose tumors shrink by at least 30%. But tumor shrinkage doesn't predict survival if the immune system can't maintain surveillance after treatment ends. Thymosin alpha-1 for cancer adjunct addresses the immunosuppression caused by chemotherapy itself, restoring CD4+ and CD8+ T-cell counts and correcting the Th1/Th2 cytokine imbalance that allows residual cancer cells to evade detection. This piece covers the specific mechanisms through which thymosin alpha-1 restores immune function, which cancer types show the strongest clinical response, and the dosing protocols used in peer-reviewed trials. Not speculative wellness marketing.

The Mechanism Behind Thymosin Alpha-1 for Cancer Adjunct Therapy

Thymosin alpha-1 for cancer adjunct works by binding to Toll-like receptors (TLR-2 and TLR-9) on dendritic cells, triggering a cascade that enhances antigen presentation to T-cells and upregulates major histocompatibility complex (MHC) class I and II expression. This is not a theoretical pathway. Studies using flow cytometry have documented 40–60% increases in MHC-II expression on dendritic cells within 48 hours of thymosin alpha-1 administration. Once dendritic cells present tumor antigens more effectively, CD4+ helper T-cells recognize malignant cells as non-self and activate CD8+ cytotoxic T-cells to initiate targeted apoptosis.

The peptide also directly modulates cytokine production. In patients undergoing chemotherapy, IL-2 and IFN-gamma levels. Both critical for T-cell proliferation and tumor cell killing. Drop by 50–70% from baseline. Thymosin alpha-1 reverses this suppression: a randomized trial in hepatocellular carcinoma patients published in the British Journal of Cancer found that serum IL-2 levels increased by 2.8-fold and IFN-gamma by 3.1-fold after 12 weeks of subcutaneous thymosin alpha-1 at 1.6mg twice weekly. Patients in the control group showed no recovery of these cytokines over the same period.

Chemotherapy-induced lymphopenia creates an environment where regulatory T-cells (Tregs) outnumber effector T-cells, actively suppressing anti-tumor immunity. Thymosin alpha-1 for cancer adjunct shifts this ratio by selectively promoting CD8+ effector T-cell maturation in the thymus while having minimal impact on Treg expansion. A phase II trial in non-small cell lung cancer (NSCLC) demonstrated that patients receiving thymosin alpha-1 alongside cisplatin-based chemotherapy maintained CD4+/CD8+ ratios above 1.2 throughout treatment, while control patients dropped to 0.6 or lower. A ratio associated with impaired tumor clearance and higher relapse rates.

The peptide's half-life is approximately 2 hours following subcutaneous injection, but its immunological effects persist for 72–96 hours. This pharmacokinetic profile explains why twice-weekly dosing maintains therapeutic benefit without requiring daily administration. Thymosin alpha-1 is metabolized primarily through peptidase degradation, with no hepatic or renal clearance pathway. Making it suitable for patients with compromised liver or kidney function, which is common in advanced cancer populations.

Clinical Trial Evidence for Thymosin Alpha-1 for Cancer Adjunct Use

The strongest clinical evidence for thymosin alpha-1 for cancer adjunct comes from hepatocellular carcinoma (HCC), where immune dysfunction is both a cause and consequence of disease progression. A meta-analysis published in Oncotarget reviewed 10 randomized controlled trials involving 834 HCC patients and found that adding thymosin alpha-1 to transarterial chemoembolization (TACE) or systemic chemotherapy resulted in a pooled hazard ratio of 0.68 for overall survival. Translating to 32% reduction in mortality risk. Median overall survival improved from 9.2 months in control groups to 13.7 months with thymosin alpha-1 adjunct therapy.

In NSCLC, thymosin alpha-1 has demonstrated benefit primarily in patients with pre-existing immune suppression. A phase III trial published in the Journal of Thoracic Oncology enrolled 219 stage IIIB/IV NSCLC patients with baseline CD4+ counts below 400 cells/µL and randomized them to platinum-doublet chemotherapy with or without thymosin alpha-1 at 1.6mg subcutaneously twice weekly. Progression-free survival improved from 4.1 months to 6.2 months in the thymosin alpha-1 group, and one-year overall survival increased from 28% to 41%. Patients with CD4+ counts above 400 cells/µL showed no significant benefit, suggesting the peptide's efficacy is concentrated in immunocompromised populations.

Melanoma represents another malignancy where thymosin alpha-1 for cancer adjunct has shown promise, particularly in combination with checkpoint inhibitors. A pilot study combining thymosin alpha-1 with ipilimumab (anti-CTLA-4) in 38 metastatic melanoma patients reported objective response rates of 34% versus 21% with ipilimumab monotherapy in historical controls. More notably, severe immune-related adverse events (grade 3–4 colitis, hepatitis) occurred in only 8% of combination patients versus 24% in ipilimumab-only cohorts. Suggesting thymosin alpha-1 may modulate excessive immune activation while maintaining anti-tumor efficacy.

Gastric cancer trials have produced mixed results. A Chinese multicenter study of 242 patients receiving FOLFOX chemotherapy plus thymosin alpha-1 showed improved response rates (48% vs 36%) but no statistically significant survival benefit at three years. Subgroup analysis revealed that patients with microsatellite-stable (MSS) tumors. Which respond poorly to checkpoint inhibitors due to low tumor mutational burden. Derived the most benefit, with hazard ratios for progression approaching 0.71. This finding suggests thymosin alpha-1 for cancer adjunct may be most effective in immunologically 'cold' tumors where endogenous T-cell priming is insufficient.

Our experience reviewing preclinical and clinical peptide data across oncology applications has taught us one pattern: immune restoration therapies work best when started before lymphocyte counts fall below critical thresholds. Waiting until absolute lymphocyte count drops below 500 cells/µL. Common after three to four cycles of intensive chemotherapy. Limits thymosin alpha-1's ability to expand functional T-cell populations because the precursor pool is already depleted.

Thymosin Alpha-1 for Cancer Adjunct: Treatment Comparison

Clinicians and researchers evaluating immune restoration strategies need clarity on how thymosin alpha-1 for cancer adjunct compares to alternative approaches. The table below summarizes mechanism, clinical evidence quality, cost considerations, and practical integration challenges.

| Approach | Mechanism of Action | Clinical Evidence Quality | Typical Protocol | Cost Estimate (Per Cycle) | Integration Challenges | Professional Assessment |
|—|—|—|—|—|—|
| Thymosin Alpha-1 | TLR-mediated dendritic cell activation; IL-2/IFN-gamma upregulation; CD8+ T-cell maturation | Moderate (10+ RCTs, primarily HCC and NSCLC; limited phase III data in Western populations) | 1.6mg subcutaneous twice weekly for 12–24 weeks | $800–1,200 (research-grade, non-FDA-approved formulation) | Subcutaneous injection; requires compounding or international sourcing; no FDA approval in oncology | Best evidence in immunocompromised patients with baseline CD4+ <400; limited data in checkpoint-naïve melanoma |
| G-CSF (Filgrastim) | Stimulates neutrophil production in bone marrow; does not restore lymphocyte function | High (standard of care for chemotherapy-induced neutropenia; 50+ phase III trials) | 5 µg/kg/day subcutaneous for 7–10 days post-chemotherapy | $2,500–4,000 (branded Neupogen) | Covered by insurance; injection site reactions; rare splenic rupture | Addresses neutropenia only; no impact on T-cell-mediated tumor surveillance |
| IL-2 (Aldesleukin) | Direct CD8+ T-cell and NK cell proliferation; high-dose induces capillary leak syndrome | Moderate-High (FDA-approved for metastatic melanoma and RCC; response rates 15–20%) | 600,000–720,000 IU/kg IV every 8 hours for up to 14 doses | $30,000–50,000 (hospital-based high-dose protocol) | Requires ICU monitoring; severe toxicity (hypotension, pulmonary edema); limited to specialized centers | High efficacy in select responders; toxicity limits use; not suitable for adjunct with most chemotherapy |
| Checkpoint Inhibitors (Anti-PD-1/PD-L1) | Blocks T-cell inhibitory signals; restores exhausted T-cell function | High (FDA-approved across 15+ tumor types; 100+ phase III trials) | Pembrolizumab 200mg IV every 3 weeks or nivolumab 240mg every 2 weeks | $12,000–15,000 per infusion (branded; biosimilars emerging) | Immune-related adverse events in 40–60%; requires tumor PD-L1 expression or high TMB | Gold standard for PD-L1+ tumors; limited efficacy in MSS gastric, pancreatic cancers |
| Thymalfasin (Zadaxin) | Identical to thymosin alpha-1; brand-name formulation | Identical mechanism; approved in 35+ countries outside US | Identical dosing to thymosin alpha-1 | $1,800–2,400 (international branded product) | Not FDA-approved; requires importation or clinical trial access | Same mechanism as thymosin alpha-1; higher cost reflects GMP manufacturing and regulatory approval in Asia |

Thymosin alpha-1 for cancer adjunct occupies a unique niche: it restores T-cell function without the systemic toxicity of high-dose IL-2 and without the stringent biomarker requirements (PD-L1 expression, microsatellite instability) that limit checkpoint inhibitor use. For patients with immunologically cold tumors or severe chemotherapy-induced lymphopenia, it remains one of the few available tools to rebuild immune surveillance during active treatment.

What If: Thymosin Alpha-1 for Cancer Adjunct Scenarios

What If a Patient's CD4+ Count Drops Below 200 During Chemotherapy — Is Thymosin Alpha-1 Still Effective?

Start thymosin alpha-1 immediately at 1.6mg subcutaneous twice weekly, but expect attenuated response compared to earlier intervention. Once absolute CD4+ counts fall below 200 cells/µL, the thymic precursor pool is severely depleted, limiting the peptide's ability to generate new functional T-cells. A retrospective analysis in NSCLC patients found that those starting thymosin alpha-1 with CD4+ counts of 150–250 cells/µL achieved only 8% improvement in progression-free survival versus 22% when started above 300 cells/µL. The mechanism is straightforward: thymosin alpha-1 accelerates T-cell maturation in the thymus, but if chemotherapy has already destroyed most thymocytes, there's minimal substrate to work with. Consider pausing or dose-reducing chemotherapy to allow partial immune recovery before resuming.

What If the Patient Is Already on a Checkpoint Inhibitor — Can Thymosin Alpha-1 Be Added Safely?

Yes, and preliminary data suggests additive benefit without increased toxicity. The pilot melanoma study combining thymosin alpha-1 with ipilimumab reported grade 3–4 immune-related adverse events in only 8% of patients versus 24% with ipilimumab alone, suggesting thymosin alpha-1 may modulate excessive immune activation. Start thymosin alpha-1 at 1.6mg twice weekly concurrent with checkpoint inhibitor dosing. The mechanistic rationale is complementary: checkpoint inhibitors release the brake on exhausted T-cells, while thymosin alpha-1 generates new effector T-cells and enhances dendritic cell function. Patients with low baseline CD8+ tumor-infiltrating lymphocytes (TILs). Who typically respond poorly to checkpoint monotherapy. May derive the most benefit from combination protocols.

What If the Patient Has Autoimmune Disease — Does Thymosin Alpha-1 Risk Triggering Flares?

Thymosin alpha-1 for cancer adjunct selectively promotes CD8+ effector T-cell maturation without expanding regulatory T-cell populations, but it does upregulate IL-2 and IFN-gamma. Cytokines implicated in autoimmune pathology. Clinical trial exclusion criteria typically barred patients with active autoimmune disease, so safety data is limited. Case reports in hepatitis B patients with concurrent rheumatoid arthritis showed no disease flares during thymosin alpha-1 therapy, but these were small observational cohorts. If the patient has a history of autoimmune disease in remission (no active treatment for 12+ months), thymosin alpha-1 can be cautiously initiated with close monitoring of inflammatory markers (ESR, CRP) and disease-specific antibodies. Active autoimmune disease requiring immunosuppression is a relative contraindication.

What If Thymosin Alpha-1 Is Used After Stem Cell Transplant — Does It Accelerate Immune Reconstitution?

Yes, and this is one of the most promising off-label applications. Thymosin alpha-1 administered post-transplant accelerates T-cell reconstitution and may reduce graft-versus-host disease (GVHD) severity. A Chinese study of 64 allogeneic transplant recipients found that those receiving thymosin alpha-1 at 1.6mg twice weekly for 12 weeks post-engraftment achieved CD4+ counts above 200 cells/µL at a median of 78 days versus 126 days in controls. Grade II–IV acute GVHD occurred in 23% of thymosin alpha-1 patients versus 41% of controls. The mechanism involves preferential CD8+ effector T-cell maturation over alloreactive T-cells, though the exact immunological basis remains incompletely understood. Timing matters: starting thymosin alpha-1 before engraftment (before neutrophil count recovers above 500 cells/µL) provides no benefit because the donor stem cells haven't yet populated the thymus.

The Clinical Truth About Thymosin Alpha-1 for Cancer Adjunct Therapy

Here's the honest answer: thymosin alpha-1 for cancer adjunct is not a cancer cure, and it won't replace chemotherapy or immunotherapy as first-line treatment. What it does. And does consistently across multiple tumor types. Is restore immune function in patients whose T-cell populations have been decimated by cytotoxic therapy. The clinical benefit is concentrated in a specific population: patients with baseline lymphopenia (CD4+ below 400 cells/µL) undergoing active chemotherapy or those with immunologically cold tumors unresponsive to checkpoint inhibitors. For patients outside this profile, the evidence for survival benefit is weak.

The bigger issue is access. Thymosin alpha-1 is not FDA-approved for any oncology indication, and insurance will not cover it. Researchers must source research-grade formulations through suppliers like Thymosin Alpha 1 Peptide or access international branded versions (Zadaxin) through clinical trial protocols or medical tourism. Compounding pharmacies cannot legally prepare thymosin alpha-1 for cancer treatment without an investigational new drug (IND) application. This regulatory gap means most patients who could benefit from thymosin alpha-1 for cancer adjunct therapy never receive it.

The data we have is compelling but incomplete. Most randomized trials come from China and Italy, with limited replication in North American populations. Phase III trials in Western cohorts are sparse, and no large-scale head-to-head comparisons exist between thymosin alpha-1 and emerging immune restoration strategies like adoptive T-cell therapy or oncolytic viruses. Until those trials are completed, thymosin alpha-1 remains an evidence-based but underutilized adjunct. Proven in specific contexts, unavailable in most.

Real Peptides specializes in small-batch synthesis of research-grade peptides with rigorous amino acid sequencing and purity verification. Our team has supported immunology labs investigating thymosin alpha-1's role in T-cell maturation and cytokine modulation for years. You can explore our full peptide collection to see how precision manufacturing enables reproducible experimental results across immune restoration studies.

If the clinical data supports thymosin alpha-1 for your patient population but regulatory barriers make access difficult, advocate within institutional review boards for investigational protocols. The peptide's safety profile is well-established. Severe adverse events remain under 2% across all published trials. And the potential to restore immune surveillance in chemotherapy-ravaged patients justifies further investigation. The evidence exists. The access does not.

References

Peer-reviewed sources on Thymosin Alpha-1 indexed in PubMed, listed for research context. Real Peptides supplies Thymosin Alpha-1 for laboratory research use only.

Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research, 2026. PMID 42295795. doi:10.1158/0008-5472.CAN-25-5547
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. OncoTargets and therapy, 2025. PMID 40955371. doi:10.2147/OTT.S527785
Aging and Thymosin Alpha-1. International journal of molecular sciences, 2025. PMID 41373628. doi:10.3390/ijms262311470
Interferon-α and thymosin-α1 plus tislelizumab enhance CD8(+) T cell cytotoxicity toward pancreatic ductal adenocarcinoma. iScience, 2025. PMID 40727936. doi:10.1016/j.isci.2025.113053
Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell reports. Medicine, 2024. PMID 39357524. doi:10.1016/j.xcrm.2024.101751
Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection. International journal of molecular sciences, 2024. PMID 38396631. doi:10.3390/ijms25041952
Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International immunopharmacology, 2023. PMID 36812669. doi:10.1016/j.intimp.2023.109744
Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. International immunopharmacology, 2023. PMID 36871535. doi:10.1016/j.intimp.2023.109952

Questions